Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BeiGene : Added to FTSE Russell Indices

09/21/2021 | 06:35am EDT


© MT Newswires 2021
All news about BEIGENE, LTD.
10/21INSIDER SELL : Beigene
MT
10/21BEIGENE : and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatme..
PU
10/21BEIGENE, LTD. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
10/21BEIGENE : Russia Approves BeiGene's Cancer Medicine for Treatment of Mantle Cell Lymphoma
MT
10/20BEIGENE : Brukinsa Gets Russian Approval to Treat Certain Patients With Mantle Cell Lympho..
MT
10/20BEIGENE : and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatme..
BU
10/20Beigene and Nanolek Announce Approval in Russia for Brukinsa? (Zanubrutinib) for Treatm..
CI
10/14BEIGENE : SVB Leerink Adjusts Price Target on BeiGene to $414 From $417, Maintains Outperf..
MT
10/14BeiGene, Ltd. Provides Contract Update with Celgene Logistics Sàrl
CI
10/13BEIGENE : Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) fo..
PU
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2021 1 246 M - -
Net income 2021 -1 167 M - -
Net cash 2021 3 810 M - -
P/E ratio 2021 -32,9x
Yield 2021 -
Capitalization 35 360 M 35 360 M -
EV / Sales 2021 25,3x
EV / Sales 2022 23,6x
Nbr of Employees 6 400
Free-Float 68,2%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 378,88 $
Average target price 433,96 $
Spread / Average Target 14,5%
EPS Revisions
Managers and Directors
John V. Oyler Chairman & Chief Executive Officer
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Jane E. Huang Chief Medical Officer-Hematology
Yong Ben Chief Medical Officer-Immuno & Oncology Department
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.46.63%35 360
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610